TY - JOUR
T1 - Dose response and atypical antipsychotics in schizophrenia
AU - Kinon, Bruce J.
AU - Ahl, Jonna
AU - Stauffer, Virginia L.
AU - Hill, Angela L.
AU - Buckley, Peter F.
N1 - Funding Information:
This work was funded by Eli Lilly and Company, Indianapolis, IN, USA. The authors have no conflicts of interest that are directly relevant to the content of this review.
PY - 2004
Y1 - 2004
N2 - Based on information from clinical trials, both the efficacy and adverse effects of conventional antipsychotics in the treatment of schizophrenia are dose related. The overlapping nature of these dose-response profiles limits the use of these agents. Atypical antipsychotics provide greater relief across the comorbid symptom domains of schizophrenia, but dose-response studies and clinical experience have revealed that some of these drugs also have dose limitations. This article reviews the dose-response relationships of the atypical antipsychotics as presented predominantly in pivotal, randomised studies (double-blind and otherwise). Limited data indicate that clozapine shows dose-related efficacy up to 600 mg/ day in patients with treatment-resistant schizophrenia. However, higher dosages of clozapine may be associated with the risk of seizures. Risperidone demonstrates dose-related adverse events that compromise efficacy. The dose-response relationships for ziprasidone, quetiapine and aripiprazole are less well established. The efficacy of olanzapine appears to be dose related within the recommended dosage range of 10-20 mg/day, but clinical trials that have explored higher dosages suggest improved efficacy. Furthermore, the higher doses are not associated with a significantly increased incidence of adverse events. Further studies are clearly needed to fully characterise the dose-response relationships of atypical antipsychotics.
AB - Based on information from clinical trials, both the efficacy and adverse effects of conventional antipsychotics in the treatment of schizophrenia are dose related. The overlapping nature of these dose-response profiles limits the use of these agents. Atypical antipsychotics provide greater relief across the comorbid symptom domains of schizophrenia, but dose-response studies and clinical experience have revealed that some of these drugs also have dose limitations. This article reviews the dose-response relationships of the atypical antipsychotics as presented predominantly in pivotal, randomised studies (double-blind and otherwise). Limited data indicate that clozapine shows dose-related efficacy up to 600 mg/ day in patients with treatment-resistant schizophrenia. However, higher dosages of clozapine may be associated with the risk of seizures. Risperidone demonstrates dose-related adverse events that compromise efficacy. The dose-response relationships for ziprasidone, quetiapine and aripiprazole are less well established. The efficacy of olanzapine appears to be dose related within the recommended dosage range of 10-20 mg/day, but clinical trials that have explored higher dosages suggest improved efficacy. Furthermore, the higher doses are not associated with a significantly increased incidence of adverse events. Further studies are clearly needed to fully characterise the dose-response relationships of atypical antipsychotics.
UR - http://www.scopus.com/inward/record.url?scp=3242659711&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=3242659711&partnerID=8YFLogxK
U2 - 10.2165/00023210-200418090-00005
DO - 10.2165/00023210-200418090-00005
M3 - Review article
C2 - 15222776
AN - SCOPUS:3242659711
SN - 1172-7047
VL - 18
SP - 597
EP - 616
JO - CNS Drugs
JF - CNS Drugs
IS - 9
ER -